Bartonellosis remains a major problem in Peru, but many contemporary aspects of this disease have not been adequately described. We examined the cases of 145 symptomatic patients in Lima, Peru, in whom bartonellosis was diagnosed from 1969 through 1992, including 68 patients in the acute (hematic) phase and 77 patients in the eruptive (verruga) phase. In modern Peru, symptomatic patients who have acute-phase bartonellosis typically present with a febrile illness and systemic symptoms caused by profound anemia; most patients respond successfully to treatment with chloramphenicol. Patients who have eruptive-phase bartonellosis most often present with cutaneous verrugas but may have less specific symptoms, such as fever and arthralgias; diagnosis can be confirmed in such patients by Western immunoblotting, and most patients appear to respond to treatment with rifampin.
for these 2 diseases [1, 3] . He died from bartonellosis in October 1885.
Although Alberto Barton identified Bartonella bacilliformis within erythrocytes in 1905, relatively little was known about other Bartonella species until recent years. In the 1990s, however, several major discoveries expanded knowledge of the genus Bartonella. First, investigators determined that either Bartonella henselae or Bartonella quintana could cause AIDS-related bacillary angiomatosis-a disease with manifestations that often include nodular skin lesions that are similar in appearance to verruga peruana lesions [4, 5] . Second, serologic, PCR, and culture data established that B. henselae was the predominant causative agent of cat-scratch disease [6] [7] [8] . Third, several groups identified Bartonella species in patients who had culture-negative endocarditis [9, 10] . Study of Bartonella has revealed that at least 12 Bartonella species cause disease in humans or animals [2, 11] .
As interest in Bartonella species has grown in recent years, desire to better understand contemporary B. bacilliformis infection has been renewed. Unfortunately, most descriptions of bartonellosis are based on old and sporadic case reports. Moreover, these reports have not clearly defined many aspects of this disease, such as the spectrum of clinical illness, the accuracy of laboratory diagnostic tests, the response to antimicrobial therapy, and the factors associated with poor outcome. To better characterize B. bacilliformis infections, we have prospectively analyzed epidemiologic, clinical, and laboratory data obtained from 145 symptomatic patients in whom bartonellosis was diagnosed from 1969 through 1992 at the "Alexander von Humboldt" Institute of Tropical Medicine in Lima, Peru.
METHODS

Setting.
The study was performed in Lima, Peru, at the Infectious Diseases Ward of the Hospital National Cayetano Heredia site of the "Alexander von Humboldt" Institute of Tropical Medicine of the Universidad Peruana Cayetano Heredia. From February 1969 through September 1992, patients for whom the diagnosis of bartonellosis was suspected were evaluated at the center and entered in the study if they fit the case definition for bartonellosis in either the acute phase or the eruptive phase.
Case definitions. The case definition for acute-phase bartonellosis required that patients have (1) at least 1 clinical manifestation associated with the acute phase (temperature у38ЊC, hematocrit !38%, jaundice, flu-like symptoms, generalized lymphadenopathy, or myalgias) and (2) either a positive blood smear for B. bacilliformis (using Giemsa or Wright stain) or a positive culture for B. bacilliformis (blood or bone marrow). We classified patients in the acute phase by whether they had complications (infectious or noninfectious complications) or did not have complications. Patients with noninfectious complications included those who presented with complications or developed complications in the hospital. Infectious complications were diagnosed either by serologic tests, specific cultures, histologic tests, or other comparable tests that demonstrated the infectious agent.
The case definition for eruptive-phase bartonellosis required that patients have clinical manifestations associated with the eruptive phase (the presence of either miliary, nodular, or mular cutaneous lesions) and characteristic findings on biopsy of 1 of the lesions (hyperplasia of endothelial cells with swollen nuclei, abundant mitosis, and proliferation of capillaries). We classified the treatment response of patients in the eruptive phase in 3 groups-"good," "fair," or "poor"-according to the patient's clinical response to a 10-day course of antibiotics. A good response consisted of a decrease in size and improvement in color (pale instead of red) of у90% of the lesions, a fair response was a decrease in size and improvement in color of 50%-90% of the lesions, and a poor response was a decrease in size and improvement in color of !50% of the lesions.
Laboratory tests. Thin-film blood smears were stained with Wright and Giemsa stains, and the percentage of parasites was calculated by counting the percentage of RBCs that contained intraerythrocytic organisms in 10 fields at magnification ϫ1000. Cultures for B. bacilliformis were done on blood and bone marrow samples. Cultures were done on lymph node samples from 7 patients. Enriched medium was used (Colichon's medium, consisting of soy agar plus sheep hemoglobin plus alanine) and was incubated at 25Њ-28ЊC. Bartonella species were identified by the typical colony morphology (described as small raindrops) and the characteristic appearance of motile, gram-negative bacilli. We analyzed serum samples from 21 patients (9 patients in the acute phase of the disease and 12 patients in the eruptive phase) using ELISA and Western immunoblotting. Beginning in 1991, all patients with a diagnosis of bartonellosis underwent routine echocardiography.
Statistical analysis. We compared differences between the variables by x 2 test or, where appropriate, Fisher's exact test. To compare means, we used Student's t test. We calculated relative risk and performed univariate and multivariate analyses using SPSS (SPSS, Inc.).
RESULTS
Epidemiology.
A total of 145 patients met enrollment criteria, 68 (47%) of whom were in the acute phase and 77 (53%) of whom were in the eruptive phase. Eighty-five (59%) were natives from areas in Peru where bartonellosis was endemic, and 60 (41%) were visitors to such areas. All the visitors were Peruvian. Five (3%) of 145 cases occurred from February 1969 through 1973, 13 (9%) from 1974 through 1978, 53 (37%) from 1979 through 1983, 36 (25%) from 1984 through 1988, and 38 (26%) from 1989 through September 1992. Forty-nine (72%) of 68 patients presenting in the acute phase were male, whereas 42 (55%) of 77 patients presenting in the eruptive phase were male. Seventy-one (49%) of the 145 patients were !14 years old; overall, patients in the acute phase were younger (mean, 14.6 years; range, 1-41 years) than patients in the eruptive phase (mean, 18.4 years; range, 1-60 years).
Clinical manifestations. Eight (12%) of 68 patients in the acute phase were admitted to the hospital with a presumptive diagnosis other than bartonellosis; these misdiagnoses included typhoid fever, malaria, brucellosis, viral hepatitis, tuberculosis, leptospirosis, meningitis, hematologic malignancy, hemolytic anemia, and aplastic anemia. In the course of the hospital admission of these 8 patients, the diagnosis of acute bartonellosis was suspected and subsequently confirmed by thin-film blood smear or culture.
The clinical features of patients in the acute phase are shown in table 1. The most common findings were fever (usually sustained, but with temperature no greater than 39ЊC), pallor, malaise, nonpainful hepatomegaly, and lymphadenopathy. Among the 47 patients with lymphadenopathy, 25 had generalized lymphadenopathy, 18 had cervical lymphadenopathy only, 2 had inguinal lymphadenopathy, and 2 had axillary lymphadenopathy. In general, the lymph nodes were moderately enlarged (1.5-3 cm), nonpainful, soft, and nonadherent. Funduscopic abnormalities included flame-shaped hemorrhages in 7 patients, cotton-wool exudates in 4 patients, and bilateral papilledema in 1 patient. Among the 6 patients with anasarca, 4 developed anasarca during the stay in the hospital, 2 had a serum albumin level !3 g/dL, and 3 died. Eighteen patients had altered mental status, 6 developed seizures, 6 showed meningeal signs, 6 experienced coma, and 2 had hemiparesis. Both patients with hemiparesis were !5 years of age, and the hemiparesis resolved completely in 2-3 weeks. Among patients in the eruptive phase, 15 (19%) of 77 were misdiagnosed on their first visit. The diagnoses given were skin tumor (7 patients), hemangioma (5 patients), polyarthralgias (2 patients), and systemic lupus erythematosis (1 patient). Only 4 (5%) of 77 patients had a clear history of an acute febrile phase that occurred months before the eruptions, and only 3 of those had required prior hospitalization. In table 2, we have summarized the clinical presentations of the patients with eruptive-phase bartonellosis. Ten (13%) of the 77 patients required admission to the hospital. Three types of cutaneous lesions were observed: miliary, nodular (subdermic), and mular. The miliary lesions characteristic of bartonellosis typically consist of multiple 1-4-mm papular, erythematous, round lesions that frequently are associated with pruritus ( figure 1A) . Nodular (or subdermic) lesions are generally few in number, appear as a subdermal nodule without changes in the overlying skin, and do not cause pruritus (figure 1B). Mular lesions are typically 15 mm in diameter and erythematous and bleed easily; pruritus, if present, is mild ( figure 1C) . The most common lesions we observed were the miliary form (in 69% of patients), and they were most often located on the lower extremities. Two patients had conjunctival lesions, 2 had lesions in the nasal mucosa, 1 had an oral cavity lesion, and 1 had lesions at all 3 of these sites. Complications of the lesions included bleeding in 51 patients (66%) and secondary infection in 9 patients (12%).
Laboratory findings. All 68 patients in the acute phase had intra-erythrocytic organisms consistent with B. bacilliformis identified on a thin-film blood smear (figure 2). The mean percentage of infected RBCs was 61% (range, 2%-100%), and contrast, only 1 (14%) of 7 cervical lymph node biopsy samples grew B. bacilliformis. Nine culture-positive patients had serologic testing done in the acute phase. Results of the ELISA used to test for B. bacilliformis were positive in 8 (89%) of those 9 patients, and Western immunoblot was positive in 9 (100%) of the 9 patients.
At the time of presentation, the mean hematocrit among patients in the acute phase was 17.2% (median, 19.0%; range, 6%-38%), and 44 (65%) of the 68 patients presented with a hematocrit !19%. The results of an indirect Coombs' test were negative for 17 (94%) of the 18 patients for whom the test was done. The mean reticulocyte count was cells/L (range, 9 18.2 ϫ 10 to cells/L). The mean leukocyte count at the 9 9 0.6 ϫ 10 90 ϫ 10 time of presentation was 13,400 cells/mm 3 . The lymphocyte count was normal in 33 patients (49%), and 12 patients (17%) presented with lymphopenia; during the course of the illness, 21 (31%) of the 68 patients developed lymphopenia. Total bilirubin levels were tested in 55 patients, and the mean level was 3.5 mmol/L. Among patients who underwent the relevant testing, 16 (29%) of 56 had an increased aspartate aminotransferase level, 14 (25%) of 56 had an increased alanine aminotransferase level, and 15 (28%) of 53 had an increased alkaline phosphatase level.
Fourteen patients in the acute phase underwent lumbar puncture because of the presence of abnormal neurologic manifestations. Three (21%) of those 14 patients had increased intracranial pressure, defined as an opening pressure 120 cm. The mean CSF WBC count was 18.6 cells/mm 3 (range, 1-113 cells/ mm mononuclear cells. The mean glucose level was 75 mg/dL, and the mean protein level was 4 mg/dL. One of the 14 CSF cultures grew B. bacilliformis; this patient was in a coma on presentation and died. Autopsy findings from that patient showed cerebritis with severe brain edema. Among the 11 patients with shortness of breath who underwent echocardiography, 7 had pericardial effusion, and 3 of those 7 had moderate to severe effusions. Only 1 of the 7 patients had the pericardial effusion at the time of admission to the hospital. Forty patients had a chest radiograph done; radiography revealed cardiomegaly in 12 patients (30%) and a pleural effusion in 2 patients (5%).
Of the 77 patients with eruptive-phase bartonellosis, only 15 had a thin-film blood smear done; the results for 2 (13%) of 15 patients were positive, and both of those patients also had positive blood cultures for B. bacilliformis. No other patients in the eruptive phase had blood cultures done; laboratory tests were not routinely performed for these patients. Twenty-seven (82%) of 33 patients for whom a leukocyte count was done had normal results, and 25 (76%) of 33 patients for whom hematocrit was tested had normal results. Twelve patients had serologic testing performed; all 12 (100%) of them had positive results of ELISA and Western immunoblotting. No patient underwent a lumbar puncture or echocardiography.
Complications. Forty-six (68%) of the 68 patients with acute-phase bartonellosis developed 1 or more complications during the course of the illness. Twenty-two (32%) of 68 patients had a noninfectious complication, including congestive heart failure (14 patients), pericardial effusion (7 patients), anasarca (4 patients), and neurologic complications (altered mental status, ataxia, agitation, seizure, or coma; 12 patients). Twenty-four (35%) of the 68 patients had an infectious complication. Eight (32%) of 25 patients for whom blood cultures were done had positive results: 3 showed non-typhi Salmonella; 1, Salmonella enteritidis and a non-typhi Salmonella; 1, Salmonella typhi and Salmonella typhimurium; 1, Shigella dysenteriae (stool and bone marrow culture positive); 1, Staphylococcus aureus; and 1, Enterobacter species. Five patients experienced reactivation of toxoplasmosis, and 1 died from Toxoplasma myocarditis confirmed by myocardial biopsy. One patient presented with disseminated histoplasmosis and had blood and bone marrow cultures positive for Histoplasma capsulatum; the patient was treated with itraconazole and had a good response. Other infections included 1 case of Pneumocystis carinii pneumonia and 1 case of Plasmodium vivax malaria.
Antimicrobial therapy. Sixty-seven (99%) of the 68 patients in the acute phase received an antimicrobial; 42 (62%) received chloramphenicol alone, and 23 (34%) received chloramphenicol and another antibiotic, such as penicillin, ampicillin, cephalexin, dicloxacillin, clindamycin, trimethoprim-sulfamethoxazole, gentamicin, or ceftriaxone. One patient received ampicillin alone, and another received norfloxacin alone. In general, the treatments were given for 10 days; a few patients received 14 days of therapy.
The initial response to chloramphenicol was poor in 3 patients. One patient initially showed an 80% organism burden on blood smear. After 10 days of chloramphenicol therapy, he remained febrile and had an organism burden of 130%. Therapy was switched to penicillin; and his fever resolved and no organisms were detected after 1 week. The second patient had a 90% organism burden and also received chloramphenicol but remained febrile and had an 80% organism burden on day 10 of treatment. His treatment was switched to penicillin, and no organisms were detected by day 4 of that regimen, but he remained febrile and developed lymphadenopathy. Later, he was diagnosed with toxoplasmosis reactivation, which responded to appropriate treatment. The third patient initially had a 90% organism burden. On day 6 of chloramphenicol therapy, he remained febrile and had a 60% organism burden. One week after his treatment was changed to penicillin, the organism burden had decreased to 30%, but the patient remained febrile. His treatment was then switched to trimethoprim-sulfamethoxazole; the fever resolved within 48 h, and his blood smears were negative by day 3 of treatment. Three patients successfully treated with chloramphenicol developed eruptive-phase bartonellosis within 3 months after receiving antibiotic therapy.
Patients with eruptive-phase bartonellosis received antimicrobial therapy if they presented with 110 cutaneous lesions, if the lesions were reddish (erythematous-violaceous), or if the onset of the lesions was !1 month before presentation. We based these criteria on clinical experience that suggested such patients were more likely to benefit from treatment. The average number of lesions for the patients who received treatment was 35, and the lesions were widely distributed. From 1969 through 1975, streptomycin was the drug of choice for treatment of eruptive-phase bartonellosis; after 1975, rifampin became the drug of choice. Overall, 55 (71%) of 77 patients with eruptive-phase bartonellosis received antimicrobial therapy: 46 (84%) of the 55 patients received oral rifampin at a dosage of 10 mg/kg/day for 10-14 days, and the remaining 9 patients (16%) received im streptomycin at a dosage of 15 mg/kg/day for 10 days. Thirty-seven (80%) of the 46 patients treated with rifampin had a good response, 7 (15%) had a fair response, and 2 (4%) had a poor response. Among the 9 patients who received streptomycin, 5 (56%) had a good response, 1 (11%) had a fair response, and 3 (33%) had a poor response.
Pregnancy and bartonellosis. Eight (15%) of the 54 female patients were pregnant. Five of the 8 presented in the acute phase, and 3 presented in the eruptive phase. Two of the 5 pregnant women with acute-phase bartonellosis died. The first death occurred in a woman at 28 weeks of gestation who developed non-typhi Salmonella bacteremia and sepsis. The second involved a woman at 24 weeks of gestation who was in a coma and had anasarca, renal insufficiency, and pericardial effusion at presentation. No secondary infection was documented in this patient. Among the 3 surviving pregnant patients, 1 presented on abortion with multiple secondary infectious complications, including typhoid fever (associated with S. typhi bacteremia), cholecystitis, and septic arthritis of the hip caused by S. aureus. The second surviving pregnant patient presented at 37 weeks of gestation with a urinary tract infection (caused by Escherichia coli); fetal demise was discovered after admission. The third patient was admitted with altered mental status (somnolence) and severe pallor; her baby was born without complications. Among the 3 pregnant women who had eruptivephase bartonellosis, 1 had a blood culture positive for B. bacilliformis. All 3 women received antimicrobial therapy with rifampin, and the babies were born with no complications or lesions.
Mortality. Six (9%) of the 68 patients in the acute phase died; 2 of the deaths occurred in individuals native to an area endemic for bartonellosis, and 4 occurred in visitors to an endemic area. Four (16%) of the 25 acute-phase patients with infectious complications died; all 4 were 114 years of age. Causes of death were Toxoplasma myocarditis, S. aureus bacteremia complicated by disseminated intravascular coagulopathy and renal insufficiency, S. typhi bacteremia (in a pregnant women), and pneumonia and sepsis syndrome. Two (9%) of the 22 patients with noninfectious complications died (1 of the 2 patients died in coma, and the other was a pregnant patient who developed anasarca, pericardial effusion, and renal insufficiency).
In the univariate analysis, we found that the presence of altered mental status (RR, 8.3; 95% CI, 1.4-51;
), ana-P p .09 sarca (RR, 32; 95% CI, 8.17-125; ), or petechiae (RR, P ! .001 22; 95% CI, 7.17-65; ) on admission was significantly P p .005 associated with mortality. In the multivariate analysis, only anasarca and petechiae were associated with mortality. No fatal cases were seen in patients with the eruptive phase.
DISCUSSION
We have extensively characterized the clinical and laboratory features of patients with acute or eruptive (chronic) symptomatic bartonellosis. Patients we observed with acute symptomatic bartonellosis typically developed a systemic illness characterized by fever, malaise, pallor, anorexia, hepatomegaly, lymphadenopathy, and severe anemia. These clinical findings correspond well with the proposed pathogenesis of the acute phase; namely, after B. bacilliformis is inoculated into the skin, it penetrates into endothelial cells of blood vessels, proliferates within the blood vessels, and then disseminates throughout the body, entering erythrocytes and the cells of the reticuloendothelial system [2] . The effect of bacteremia combined with resultant severe anemia presumably generates the intense acute symptoms that patients experience, particularly the fever, malaise, and pallor; the hepatomegaly and lymphadenopathy presumably result from the immune reaction to the marked dissemination of B. bacilliformis throughout the reticuloendothelial system. The anemia we have described in the acute phase was severe (mean hematocrit of 17% and mean percentage of infected erythrocytes of 61%). The findings of a mean reticulocyte count of cells/L at the time of initial 9 18.2 ϫ 10 evaluation and negative results of a Coombs' test in 17 of the 18 patients tested suggests massive hemolysis of erythrocytes by a non-antibody-mediated mechanism. Prior work has shown that B. bacilliformis (1) uses its flagella to bind and invade erythrocytes, (2) secretes a protein known as "deformin" that induces pits and invaginations in erythrocyte membranes, and (3) can directly induce hemolysis by secreting a protein distinct from deformin [12] [13] [14] [15] .
We have described several severe manifestations of acute bartonellosis, including anasarca in 6 patients, neurologic manifestations in 14 patients, and a pericardial effusion in 7 patients. The finding of anasarca appears to serve as a marker of a poor prognosis, because 3 of those 6 patients died. Although we have described a spectrum of severe manifestations associated with acute bartonellosis, prior work by others has suggested that a substantial percentage of persons infected with B. bacilliformis have an asymptomatic or minimally symptomatic course [16] . The factors that determine the severity of the clinical illness remain unknown but could be related to the inoculum size of B. bacilliformis, specific organism virulence factors, the host's nutritional status, and/or the host's immune response to B. bacilliformis. Our study did not address this issue, because all patients enrolled in the study had symptomatic disease.
We found that nearly 70% of patients with acute bartonellosis had complications and that the distribution of noninfectious and infectious complications was approximately equal. Most of the noninfectious complications may simply represent the direct consequences of severe, disseminated B. bacilliformis infection. The infectious complications, however, appear to result from transient immunosuppression that may allow the invasion of opportunistic bacteria, such as Salmonella species or Toxoplasma species. We found Salmonella species to be the most common cause of infectious complications, but we also saw an array of other pathogens. The exact mechanism for immunosuppression caused by B. bacilliformis has not been clearly identified.
Patients that we observed who had eruptive bartonellosis typically developed miliary-type lesions on the upper extremities, often associated with bleeding of the verruga, fever, and malaise. The cutaneous lesions of verruga peruana can be similar in appearance to other dermatologic lesions, such as pyogenic granuloma, hemangioma, bacillary angiomatosis, Kaposi's sarcoma, fibrosarcoma, epithelioid sarcoma, carcinoma of the sweat gland, cutaneous lymphoma, juvenile melanoma (Spitz tumor), and histioid phase of Hansen's disease. Work by Arias-Stella [17] demonstrated that patients with eruptive bartonellosis have a characteristic histologic reaction that consists of intense proliferation of newly formed capillaries and marked endothelial hyperplasia. The cellular composition of these lesions consists of a mixture of endothelial cells and dermal dendrocytes [18] , both of which may play a role in controlling B. bacilliformis.
The clinical diagnosis of bartonellosis can be challenging, as is shown by the initial misdiagnosis in 12% of patients in the acute phase and in 19% of those in the eruptive phase in our study. In the setting of acute symptomatic bartonellosis, the organism burden was high, with a mean percentage of infected RBCs of 61%; moreover, 25% of patients had levels of infected RBCs of 190% at the time of admission. Although 25 (71%) of 35 patients with acute bartonellosis had a positive blood culture for B. bacilliformis, the long delay before the culture can be determined to be positive (mean, 18 days) diminishes the clinical utility of this test in a setting in which a prompt diagnosis is needed. Nevertheless, we recommend that blood cultures be done for a patient in whom acute-phase bartonellosis is suspected, because a positive blood culture can provide definitive evidence of Bartonella infection, and patients may have concomitant bacteremia caused by other bacterial pathogens, such as Salmonella species. Although our laboratory data for patients with eruptive bartonellosis were not extensive, we found that 12 (100%) of 12 patients who underwent serologic testing for Bartonella had positive results, but only 2 (13%) of 15 patients had positive blood smears. More recently, Mallqui et al. [19] investigated an immunoblot test that uses sonication of whole B. bacilliformis and reported 94% sensitivity for patients with eruptive-phase bartonellosis and 70% sensitivity for patients with acute bartonellosis; in healthy subjects, the test showed 100% specificity. We did not present histologic data for eruptive lesions, mainly because other investigators have characterized the histopathology of these lesions very well [17, 18] .
In the preantibiotic era, the mortality associated with human bartonellosis was very high. Successful treatment of acute bartonellosis has occurred with use of many different antibiotics, including penicillin, streptomycin, erythromycin, and tetracycline, but chloramphenicol became established as the drug of choice in the 1950s because of its good activity against both the primary pathogen (B. bacilliformis) and the most common serious secondary pathogen (Salmonella species). In our study,
195% of patients received chloramphenicol in the acute phase, and ∼95% of those patients had a good response to treatment of the Bartonella infection. Three patients, each with an initial organism burden 180%, did not respond. Six patients appeared to have a good response to treatment of the Bartonella infection but died from other complications, such as secondary infections. It is interesting that successful treatment with chloramphenicol appears not to eliminate the patient's risk of subsequently developing eruptive-phase bartonellosis. Three of our acute-phase patients for whom treatment apparently was successful later developed eruptive bartonellosis. Thus, our experience shows that chloramphenicol is effective in most, but not all, patients with acute bartonellosis. Accordingly, we are interested in attempting to achieve even better responses with other oral antimicrobial agents, particularly ciprofloxacin, and thus have begun studying the response of patients with acute bartonellosis to ciprofloxacin (C.M., unpublished observations). The treatment used for the eruptive-phase bartonellosis has traditionally been administration of streptomycin at 15-20 mg/ kg/day for 10 days, but the use of im streptomycin is problematic, especially in children. In the mid-1970s, rifampin became the drug of choice for treatment of eruptive-phase bartonellosis. In our experience with treating eruptive-phase bartonellosis, ∼70% of patients received antimicrobial therapy; ∼80% of those received rifampin, and ∼20% received streptomycin. Among those who received rifampin, ∼80% had a good response. More recently, we have had success using ciprofloxacin, 500 mg b.i.d. for 7-10 days, for treatment of multiple eruptive-phase lesions in adults [2] . Recent in vitro antibiotic susceptibility testing of 4 human strains of B. bacilliformis showed susceptibility to multiple antibiotics, including most b-lactams, aminoglycosides, chloramphenicol, rifampin, macrolides, tetracyclines, cotrimoxazole, and fluoroquinolones [20] .
In our series, we found a mortality rate of 9% among patients in the acute phase and no deaths among patients in the eruptive phase of bartonellosis. In the univariate analysis, we found that anasarca, petechiae, and altered mental status were associated with fatal outcome, but only anasarca and petechiae remained statistically significant in the multivariate analysis. Our reported mortality of 9% is significantly lower than that in reports made elsewhere [3] . Our series included 8 pregnant women, 5 of whom presented in the acute phase. Of these 5 patients, 2 died,losis and pregnancy exist, it appears that acute bartonellosis poses great risk for both the pregnant mother and the fetus.
